The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood–tumor and blood–brain barriers improve outcomes in a rat glioma model
Open accessAbstract
The blood-brain-barrier (BBB) prevents the transport of most anticancer agents to the central nervous system and restricts delivery to infiltrating brain tumors. The heterogeneous vascular permeability in tumor vessels, along with several other factors, creates additional barriers for drug treatment for brain tumors. Focused ultrasound (FUS), when combined with circulating microbubbles, is an emerging noninvasive method to temporarily permeabilize the BBB and the “blood-tumor barrier”. Here, we tested the impact of three weekly sessions of FUS and liposomal doxorubicin (DOX) in 9L rat glioma tumors. Animals that received FUS + DOX (N = 8) had a median survival time that was increased significantly (P < 0.001) compared to animals who received DOX only (N = 6), FUS only (N = 8), or no treatment (N = 7). Median survival for animals that received FUS + DOX was increased by 100% relative to untreated controls, whereas animals who received DOX alone had only a 16% improvement. Animals who received only FUS showed no improvement. No tumor cells were found in histology in 4/8 animals in the FUS + DOX group, and in two animals, only a few tumor cells were detected. Adverse events in the treatment group included skin toxicity, impaired activity, damage to surrounding brain tissue, and tissue loss at the tumor site. In one animal, intratumoral hemorrhage was observed. These events are largely consistent with known side effects of doxorubicin and with an extensive tumor burden. Overall this work demonstrates that multiple sessions using this FUS technique to enhance the delivery of liposomal doxorubicin has a pronounced therapeutic effect in this rat glioma model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Multiple significance tests: the Bonferroni method
Bland, J. M., & Altman, D. G. (1995) · BMJ · doi:10.1136/bmj.310.6973.170 · Cited by 3,341
Noninvasive MR Imaging–guided Focal Opening of the Blood-Brain Barrier in Rabbits
Hynynen, K., McDannold, N., Vykhodtseva, N., & Jolesz, F. A. (2001) · Radiology · doi:10.1148/radiol.2202001804 · Cited by 1,456
Self-citationPardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Kinoshita, M., McDannold, N., Jolesz, F. A., & Hynynen, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604318103 · Cited by 645
Self-citationSheikov, N., McDannold, N., Vykhodtseva, N., Jolesz, F., & Hynynen, K. (2004) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2004.04.010 · Cited by 617
Self-citationMcDannold, N., Arvanitis, C. D., Vykhodtseva, N., & Livingstone, M. S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0128 · Cited by 588
Self-citationTumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
McDannold, N., Clement, G. T., Black, P., Jolesz, F., & Hynynen, K. (2010) · Neurosurgery · doi:10.1227/01.neu.0000360379.95800.2f · Cited by 555
Self-citationTreat, L. H., McDannold, N., Vykhodtseva, N., Zhang, Y., Tam, K., & Hynynen, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22732 · Cited by 545
Self-citation
Cited by
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Mainprize, T., Lipsman, N., Huang, Y., Meng, Y., Bethune, A., Ironside, S., Heyn, C., Alkins, R., Trudeau, M., Sahgal, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36340-0 · Cited by 618
Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 605
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Progress and perspectives on targeting nanoparticles for brain drug delivery
Gao, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.013 · Cited by 495
Aryal, M., Arvanitis, C. D., Alexander, P. M., & McDannold, N. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.008 · Cited by 443
Self-citationProgress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387
Ultrasound-Responsive Cavitation Nuclei for Therapy and Drug Delivery
Kooiman, K., Roovers, S., Langeveld, S. A. G., Kleven, R. T., Dewitte, H., O'Reilly, M. A., Escoffre, J.-M., Bouakaz, A., Verweij, M. D., Hynynen, K., et al. (2020) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2020.01.002 · Cited by 359
A Review of Low-Intensity Ultrasound for Cancer Therapy
Wood, A. K. W., & Sehgal, C. M. (2015) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2014.11.019 · Cited by 345
Focused ultrasound-mediated drug delivery through the blood–brain barrier
Burgess, A., Shah, K., Hough, O., & Hynynen, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1028369 · Cited by 323
Strategies for transporting nanoparticles across the blood–brain barrier
Zhang, T.-T., Li, W., Meng, G., Wang, P., & Liao, W. (2016) · Biomaterials Science · doi:10.1039/c5bm00383k · Cited by 308
Liu, H.-L., Fan, C.-H., Ting, C.-Y., & Yeh, C.-K. (2014) · Theranostics · doi:10.7150/thno.8074 · Cited by 276
Gaillard, P. J., Appeldoorn, C. C. M., Dorland, R., van Kregten, J., Manca, F., Vugts, D. J., Windhorst, B., van Dongen, G. A. M. S., de Vries, H. E., Maussang, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0082331 · Cited by 273
Sun, T., Zhang, Y., Power, C., Alexander, P. M., Sutton, J. T., Aryal, M., Vykhodtseva, N., Miller, E. L., & McDannold, N. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713328114 · Cited by 258
Self-citationNanotechnology-based strategies for siRNA brain delivery for disease therapy
Zheng, M., Tao, W., Zou, Y., Farokhzad, O. C., & Shi, B. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.01.006 · Cited by 210
Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy
Upton, D. H., Ung, C., George, S. M., Tsoli, M., Kavallaris, M., & Ziegler, D. S. (2022) · Theranostics · doi:10.7150/thno.69682 · Cited by 182
Wang, J., Li, Z., Pan, M., Fiaz, M., Hao, Y., Yan, Y., Sun, L., & Yan, F. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114539 · Cited by 161
Precision Nanomedicine in Neurodegenerative Diseases
Goldsmith, M., Abramovitz, L., & Peer, D. (2014) · ACS Nano · doi:10.1021/nn501292z · Cited by 124
“An example of an interesting strategy for disruption of the BBB is the use of focused ultrasound that may open the BBB for a designated time while drugs are administered.(8) Invasive approaches can be aggressive (by mechanically breaching the BBB) and aim tomaximize the amount of drug that reaches the target site with…”
Current status and future perspectives of sonodynamic therapy in glioma treatment.
Wang, X., Jia, Y., Wang, P., Liu, Q., & Zheng, H. (2017) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2017.02.020 · Cited by 86
Zhu, H., Allwin, C., Bassous, M. G., & Pouliopoulos, A. N. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04795-z · Cited by 75
Microbubble-Assisted Ultrasound for Drug Delivery in the Brain and Central Nervous System
Burgess, A., & Hynynen, K. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-22536-4_16 · Cited by 62
Chang, K. W., Hong, S. W., Chang, W. S., Jung, H. H., & Chang, J. W. (2023) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2022.0236 · Cited by 15
Metadata
- Authors
- Aryal, M., Vykhodtseva, N., Zhang, Y.-Z., Park, J., & McDannold, N.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 169
- Issue
- 1-2
- Pages
- 103-111
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W1964956174
- Cited by
- 261
- References
- 45
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.